Phase II Study of SOL and Bevacizumab Combination Therapy in patients with Untreated Metastatic Colorectal Cancer.
Phase 2
- Conditions
- ntreated metastatic colorectal cancer
- Registration Number
- JPRN-jRCT2080220850
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Adequate oral intake
At least one measurable lesion by RECIST criteria.
ECOG Performance status:0-1
Exclusion Criteria
Serious drug hypersensitivity
Prior history of peripheral neuropathy
Diarrhea
Simultaneously active double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method